Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sanofi Pasteur H7N9 Vaccine with/without AS03 in Healthy Adults
NCT03312231Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of inactivated influenza H7N9 vaccine in Avian Influenza (AI), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2018; status: completed.
02
Drugs
inactivated influenza H7N9 vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03312231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312231.